AddTweet Post to Facebook hEmail this
‹‹ Go Back

Geetha A. Subramaniam, MD, DFAPA

Deputy Director, National Institute on Drug Abuse, Bethesda, Maryland

Geetha Subramaniam is the Deputy Director of the Center for Clinical Trials Network at NIDA where she leads several multisite clinical studies related to substance use disorders. She is ABPN certified in Child and Adolescent Psychiatry, Addiction Psychiatry and General Psychiatry and is in part-time private practice in Bethesda, MD. Dr. Subramaniam has had extensive clinical experience in the treatment of adolescents and young adults with substance use disorders and research experience examining the treatment and outcomes of opioid use disorders in youth. She has authored several peer-reviewed journal articles and has presented at numerous premier national conferences. She is also an adjunct faculty at the Johns Hopkins University School of Medicine, where she conducted original research, provided clinical services and supervised and taught residents.

‹‹ Go Back

Andrew J. Saxon, MD

Professor and Director, Center of Excellence in Substance Abuse Treatment and Education, University of Washington and VA Puget Sound Health Care System, Seattle, Washington

presenter photoAndrew J. Saxon, M.D. Professor, Department of Psychiatry and Behavioral Sciences, University of Washington Director, Center of Excellence in Substance Abuse Treatment and Education, VA Puget Sound Health Care System Director, Addiction Psychiatry Residency Program, University of Washington Preceding his entry into psychiatry, Dr. Saxon completed an internal medicine internship and worked for 4 years as an emergency room physician. Subsequent to his general psychiatry residency at the University of Washington, Dr. Saxon has more than a quarter century of experience as a clinical and research addiction psychiatrist. Dr. Saxon is board certified with added qualifications in addiction psychiatry by the American Board of Psychiatry and Neurology. Dr. Saxon sits on the editorial boards of the journals, Drug and Alcohol Dependence and General Hospital Psychiatry. Dr. Saxon’s current research work is supported by the VA, the Department of Defense, and the National Institute on Drug Abuse and involves pharmacotherapies and psychotherapies for alcohol, cocaine, tobacco, and opioid use disorders as well work in co-occurrence of substance use disorders and posttraumatic stress disorder and on reducing homelessness.

‹‹ Go Back

Larissa J. Mooney, MD

Assistant Clinical Professor, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California

presenter photoDr. Larissa Mooney is a board certified addiction psychiatrist with expertise in the treatment of substance use disorders and psychiatric comorbidity. After obtaining residency training at New York University, she completed a fellowship in addiction psychiatry at Cedars-Sinai Medical Center in 2006. Dr. Mooney is an Assistant Clinical Professor of Psychiatry at UCLA and Director of the UCLA Addiction Medicine Clinic, where she supervises and teaches psychiatrists in training in both inpatient and outpatient clinical settings. Dr. Mooney has conducted research on treatment interventions for addictive disorders at UCLA Integrated Substance Abuse Programs since 2007 and has collaborated on community training initiatives to enhance understanding of substance abuse and concomitant psychiatric illness among mental health clinicians. She is a Co-Investigator for the Pacific Region Node of the NIDA Clinical Trials Network. Her interests include development of psychopharmacological and integrated treatments for addiction and advancement of substance abuse training for health care professionals.

‹‹ Go Back

Madhukar H. Trivedi, MD

Professor, University of Texas Southwestern Medical Center, Dallas, Texas



‹‹ Go Back

Theresa M. Winhusen, PhD

Professor and Director, Addiction Sciences Division, University of Cincinnati College of Medicine, Cincinnati, Ohio

presenter photoDr. Winhusen is the Director of the Addiction Sciences Division and a Professor of Psychiatry at the University of Cincinnati College of Medicine. Throughout the last 18 years, Dr. Winhusen has conducted NIDA-funded research to identify effective substance abuse treatments with a particular emphasis on treating nicotine and cocaine use disorders. She has been the national PI or Co-PI for six multi-site clinical trials in NIDA’s Clinical Trials network (CTN) since 2001. Dr. Winhusen has over 70 peer-reviewed publications and is a member of the College on Problems of Drug Dependence.

‹‹ Go Back

Please enter your access key

The asset you are trying to access is locked for premium users. Please enter your access key to unlock.


Email This Presentation:

From:

To:

Subject:

Body:

Focus Session Track

Updates from the NIDA Clinical Trials Network: Management of Stimulant Use Disorders

4/24/2015

4:00 PM - 5:30 PM

Room: 400/402, Fourth Floor

Organizer (Presenting)(s):

Geetha A. Subramaniam, MD, DFAPA

Deputy Director, National Institute on Drug Abuse, Bethesda, Maryland

Presenter(s):

Andrew J. Saxon, MD

Professor and Director, Center of Excellence in Substance Abuse Treatment and Education, University of Washington and VA Puget Sound Health Care System, Seattle, Washington

Larissa J. Mooney, MD

Assistant Clinical Professor, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California

Madhukar H. Trivedi, MD

Professor, University of Texas Southwestern Medical Center, Dallas, Texas

Theresa M. Winhusen, PhD

Professor and Director, Addiction Sciences Division, University of Cincinnati College of Medicine, Cincinnati, Ohio

The NIDA National Drug Abuse Treatment Clinical Trials Network (CTN) has conducted several trials exploring innovative interventions for the management of cocaine or methamphetamine use disorders. Experts will present findings from these cutting-edge treatment intervention trials, which have examined combined medication strategies for addressing cocaine and methamphetamine use, the utility of dosed physical exercise as a behavioral intervention, and the efficacy of pharmacotherapy for cocaine relapse prevention. The CTN trials to be discussed are the following: (1) Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Dependence (ADAPT-MD), a study testing the combination of bupropion and extended-release depot naltrexone; (2) Cocaine Use Reduction with Buprenorphine (CURB), a study testing the combination of buprenorphine and extended-release depot naltrexone; (3) Stimulant Reduction Intervention using Dosed Exercise (STRIDE); and (4) Buspirone for Relapse-Prevention in Adults with Cocaine Dependence (BRAC).